Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$55.97
-0.28-0.50%
At close: Dec 15, 4:00 PM EST
$55.66
-0.31-0.55%
Pre-Market: 4:08 AM EST
Comments
Loading...
CRISPR Therapeutics (CRSP) Stock Price, Quote, News & History
CRSPNASDAQ
Edge Rankings
Stock Score Locked: Want to See it?
Benzinga Rankings give you vital metrics on any stock – anytime.
Compare
EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
EPS worse than industry
FAQ
How do I buy CRISPR Therapeutics (CRSP) stock?
You can purchase shares of CRISPR Therapeutics (NASDAQ:CRSP) through any online brokerage.
Who are CRISPR Therapeutics (CRSP) competitors?
Other companies in CRISPR Therapeutics’s space includes: Immunovant Inc (NASDAQ:IMVT), Legend Biotech Corp (NASDAQ:LEGN), Cogent Biosciences Inc (NASDAQ:COGT), Celcuity Inc (NASDAQ:CELC) and Centessa Pharmaceuticals PLC (NASDAQ:CNTA).
What is the forecast, or price target, for CRISPR Therapeutics (CRSP) stock?
CRISPR Therapeutics has a consensus price target of $71.57.
What is the current price for CRISPR Therapeutics (CRSP)?
The stock price for CRISPR Therapeutics (NASDAQ: CRSP) is $55.66 last updated December 17, 2025 at 4:00 AM EST.
Does CRISPR Therapeutics (CRSP) pay a dividend?
There are no upcoming dividends for CRISPR Therapeutics.
When is CRISPR Therapeutics (NASDAQ:CRSP) reporting earnings?
CRISPR Therapeutics does not have any upcoming earnings scheduled.
Is CRISPR Therapeutics (CRSP) going to split?
There is no upcoming split for CRISPR Therapeutics.
What sector and industry does CRISPR Therapeutics (CRSP) operate in?
CRISPR Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
